Figure 4.
MiRNA451a and miRNA142-5p were upregulated in the responder group. qPCR analysis of miRNA451a (A) and miRNA142-5p (B) in the plasma of six patients after treatment with the camrelizumab and SOX regimen. The data were normalized with U6 values. *, P<0.05. R, responder group; NR, non-responder group; qPCR, quantitative polymerase chain reaction; SOX, S-1 plus oxaliplatin.